Previous Close | 0.0500 |
Open | N/A |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 5.00 |
Expire Date | 2024-07-19 |
Day's Range | 0.0500 - 0.0500 |
Contract Range | N/A |
Volume | |
Open Interest | 4 |
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal infections remain on track for delivery to GSK in mid 2024, which would trigger a $10 million development milestone payment to SCYNEXISSCYNEXIS ended Q1 2024 with cash, cash equivalents and investments of $94.2 million and projects a cash runway of more than two years JERSEY CITY, N.J.,
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species JERSEY CITY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentat